These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11913510)

  • 1. E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.
    Leroi MJ; Siarakas S; Gottlieb T
    Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):72-4. PubMed ID: 11913510
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from hospitals during a 4-year period in China.
    Chen YB; Gu SL; Shen P; Lv T; Fang YH; Tang LL; Li LJ
    J Med Microbiol; 2018 Jan; 67(1):52-59. PubMed ID: 29160203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibility of Clostridium difficile isolates in Israel.
    Tkhawkho L; Nitzan O; Pastukh N; Brodsky D; Jackson K; Peretz A
    J Glob Antimicrob Resist; 2017 Sep; 10():161-164. PubMed ID: 28729205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
    Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
    Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
    Rodríguez JC; Ruiz M; López M; Royo G
    Int J Antimicrob Agents; 2002 Dec; 20(6):464-7. PubMed ID: 12458143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly antibiotic-resistant Clostridium difficile isolates from Iranian patients.
    Baghani A; Ghourchian S; Aliramezani A; Yaseri M; Mesdaghinia A; Douraghi M
    J Appl Microbiol; 2018 Nov; 125(5):1518-1525. PubMed ID: 29957893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators.
    Freeman J; Vernon J; Vickers R; Wilcox MH
    Antimicrob Agents Chemother; 2016 Jan; 60(1):689-92. PubMed ID: 26552981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.
    Rodriguez Díaz JC; López M; Ruiz M; Royo G
    Int J Antimicrob Agents; 2003 Jun; 21(6):585-8. PubMed ID: 12791475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
    Harper T; Miller D; Flynn HW
    Ophthalmology; 2007 May; 114(5):871-5. PubMed ID: 17383732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model.
    Baines SD; Noel AR; Huscroft GS; Todhunter SL; O'Connor R; Hobbs JK; Freeman J; Lovering AM; Wilcox MH
    J Antimicrob Chemother; 2011 Jul; 66(7):1537-46. PubMed ID: 21504940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection.
    Chilton CH; Crowther GS; Baines SD; Todhunter SL; Freeman J; Locher HH; Athanasiou A; Wilcox MH
    J Antimicrob Chemother; 2014 Mar; 69(3):697-705. PubMed ID: 24128668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
    Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC
    J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007].
    Poilane I; Fantinato C; Cruaud P; Collignon A
    Pathol Biol (Paris); 2008; 56(7-8):412-6. PubMed ID: 18842360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization and antimicrobial susceptibilities of Clostridium difficile clinical isolates from Victoria, Australia.
    Mackin KE; Elliott B; Kotsanas D; Howden BP; Carter GP; Korman TM; Riley TV; Rood JI; Jenkin GA; Lyras D
    Anaerobe; 2015 Aug; 34():80-3. PubMed ID: 25944720
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Freeman J; Pilling S; Vernon J; Wilcox MH
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
    Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
    Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.
    Gerding DN; Hecht DW; Louie T; Nord CE; Talbot GH; Cornely OA; Buitrago M; Best E; Sambol S; Osmolski JR; Kracker H; Locher HH; Charef P; Wilcox M
    J Antimicrob Chemother; 2016 Jan; 71(1):213-9. PubMed ID: 26433782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of linezolid against Clostridium difficile.
    Peláez T; Alonso R; Pérez C; Alcalá L; Cuevas O; Bouza E
    Antimicrob Agents Chemother; 2002 May; 46(5):1617-8. PubMed ID: 11959617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile.
    Odenholt I; Walder M; Wullt M
    Chemotherapy; 2007; 53(4):267-74. PubMed ID: 17595541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emergence of metronidazole and vancomycin reduced susceptibility in Clostridium difficile isolates in Iran.
    Kouhsari E; Douraghi M; Krutova M; Fakhre Yaseri H; Talebi M; Baseri Z; Moqarabzadeh V; Sholeh M; Amirmozafari N
    J Glob Antimicrob Resist; 2019 Sep; 18():28-33. PubMed ID: 30703583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.